- Home
- ANIX vs ACET Comparison
ANIX vs ACET Comparison
Compare ANIX & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- ACET
- Stock Information
- Founded
- ANIX 1982
- ACET 1947
- Country
- ANIX United States
- ACET United States
- Employees
- ANIX N/A
- ACET N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- ANIX Health Care
- ACET Health Care
- Exchange
- ANIX Nasdaq
- ACET Nasdaq
- Market Cap
- ANIX 82.7M
- ACET 75.6M
- IPO Year
- ANIX 1987
- ACET N/A
- Fundamental
- Price
- ANIX $2.41
- ACET $0.91
- Analyst Decision
- ANIX Strong Buy
- ACET Strong Buy
- Analyst Count
- ANIX 2
- ACET 4
- Target Price
- ANIX $8.50
- ACET $5.67
- AVG Volume (30 Days)
- ANIX 121.1K
- ACET 513.3K
- Earning Date
- ANIX 01-10-2025
- ACET 11-06-2024
- Dividend Yield
- ANIX N/A
- ACET N/A
- EPS Growth
- ANIX N/A
- ACET N/A
- EPS
- ANIX N/A
- ACET N/A
- Revenue
- ANIX N/A
- ACET N/A
- Revenue This Year
- ANIX N/A
- ACET N/A
- Revenue Next Year
- ANIX N/A
- ACET N/A
- P/E Ratio
- ANIX N/A
- ACET N/A
- Revenue Growth
- ANIX N/A
- ACET N/A
- 52 Week Low
- ANIX $2.07
- ACET $0.81
- 52 Week High
- ANIX $5.09
- ACET $3.62
- Technical
- Relative Strength Index (RSI)
- ANIX 44.08
- ACET 43.86
- Support Level
- ANIX $2.07
- ACET $0.85
- Resistance Level
- ANIX $2.69
- ACET $0.94
- Average True Range (ATR)
- ANIX 0.19
- ACET 0.08
- MACD
- ANIX 0.03
- ACET 0.00
- Stochastic Oscillator
- ANIX 54.84
- ACET 22.16
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.